The North America Influenza Diagnostics Market is poised for significant growth driven by technological advancements and increasing awareness regarding early disease detection. The market size was valued at USD 1,180 million in 2025 and is projected to reach USD 2,890 million by 2035, progressing at a CAGR of 8.8% from 2024 to 2035.
The economic impact of tariffs on "North America Influenza Diagnostics Market".
Market Growth Drivers
Technological advancements in diagnostic tools, such as rapid molecular assays and point-of-care (POC) testing, are significantly boosting the North America Influenza Diagnostics Market. Companies like Abbott and Quidel have introduced innovative rapid diagnostic kits that provide results within minutes, making influenza detection more accessible in both clinical and non-clinical settings. For instance, Abbott’s ID NOW and Quidel’s Sofia platforms are widely used in hospitals and urgent care centers across the U.S., reducing diagnosis time and supporting patient management during influenza season. These advancements improve workflow efficiency and enable early intervention, facilitating better outcomes and curbing disease spread.
Increased government initiatives to strengthen flu surveillance and response are propelling the market forward. The Centers for Disease Control and Prevention (CDC) in the U.S. has increased investments in public health infrastructure, driving regional demand for influenza diagnostic tests. Collaborations between public health agencies and diagnostic test manufacturers such as Becton, Dickinson and Company (BD) have led to the widespread availability of high-sensitivity and high-specificity influenza detection tests at national and local levels, ensuring rapid identification of cases during outbreaks and pandemics.
Market Trends
The adoption of multiplex testing platforms is a prominent trend in the North America Influenza Diagnostics Market. Multiplex assays, developed by companies such as Roche and Thermo Fisher Scientific, enable simultaneous detection of influenza A, influenza B, and other respiratory pathogens, streamlining workflows and reducing diagnostic costs. As seasonal flu increasingly co-circulates with other respiratory viruses (e.g., RSV, SARS-CoV-2), hospitals and laboratories are investing in these platforms to improve diagnostic accuracy and efficiency.
Another key trend is the growing use of digital health solutions, including telemedicine-enabled home testing and remote patient management. Innovators like Cue Health have launched FDA-authorized influenza testing devices designed for home use, allowing patients to obtain reliable results and consult with healthcare professionals remotely. This shift not only addresses patient convenience and safety in a post-pandemic context but also supports ongoing market expansion by extending diagnostic capabilities beyond traditional clinical settings.
Market Opportunities
Expansion into underserved rural and remote areas represents a significant opportunity for market participants. Companies like Quidel and Cepheid are developing portable, user-friendly diagnostic devices that can be deployed in clinics with limited laboratory infrastructure, increasing access to timely influenza diagnosis and supporting public health interventions.
Strategic collaborations with government health agencies for emergency preparedness and outbreak response open new growth avenues. By partnering on pandemic preparedness programs, firms can secure large-volume contracts for influenza tests, enhancing supply chain robustness and market penetration.
North America Influenza Diagnostics Market Revenue (USD Million), 2020-2035
The provided chart illustrates the steady growth trajectory of the North America Influenza Diagnostics Market from 2020 through 2035. Revenue increased from USD 760 million in 2020, reflecting heightened demand due to public health initiatives amid the COVID-19 pandemic, to USD 1,180 million by 2025. The market is projected to reach approximately USD 2,890 million by 2035, driven by technological advances, wider testing adoption, and robust healthcare infrastructure. The consistent upward trend highlights the market’s resilience, with significant revenue surges corresponding to new product launches, expanded test coverage, and increased awareness for early influenza diagnosis.
North America Influenza Diagnostics Market by Regional Share (%), 2025
The 2025 regional market share distribution pie chart shows that the United States continues to dominate the North America Influenza Diagnostics Market, accounting for approximately 72% of the total market value. Canada follows with 21% share, driven by rising healthcare expenditure and adoption of advanced diagnostics. Mexico holds 5%, attributable to expanding healthcare infrastructure. The remaining 2% is split between other regions such as Puerto Rico and Bermuda, which contribute minor shares due to relatively smaller healthcare markets. This distribution emphasizes the leading role of the U.S. in the market, propelled by robust demand and substantial investments in public health.
Recent Developments in North America Influenza Diagnostics Market
In March 2024, Abbott announced the launch of its new Alinity m Resp-4-Plex assay in the U.S. market. This advanced multiplex test can simultaneously detect influenza A, influenza B, RSV, and SARS-CoV-2 from a single patient sample. The product received FDA Emergency Use Authorization (EUA), offering healthcare providers a rapid and comprehensive respiratory testing solution as the U.S. approaches the flu season. Abbott plans to expand production in its Illinois manufacturing site to meet the growing demand.
In May 2024, QuidelOrtho received Health Canada approval for its Sofia 2 Flu+SARS Antigen FIA, expanding access to combined flu and COVID-19 testing for clinics and pharmacies across Canada. This approval supports public health authorities in scaling up surveillance and improving patient triage during periods of high respiratory illness incidence. The company is partnering with Canadian distributor Medline to ensure rapid deployment nationwide.
In February 2024, Thermo Fisher Scientific strengthened its regional presence by establishing a dedicated respiratory diagnostics R&D hub in Toronto, Canada. This facility aims to accelerate development and customization of influenza and multiplex respiratory pathogen tests tailored to the North American market. The hub will foster innovation and facilitate closer collaboration with local healthcare providers, supporting detection and monitoring of evolving influenza strains in the region.
Press Releases